Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 8/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.35 |
| ▸ | PPARD | Q03181 | 4/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339990 | 0.86 | PPARA (0.43) | CYP4F2CYP4A11MMP8PPARAPPARG | |
| SCHEMBL5384008 | 0.86 | ESR1 (0.45) | PPARA | |
| SCHEMBL3991226 | 0.86 | ESR1 (0.45) | PPARA | |
| SCHEMBL13819361 | 0.86 | CYP4F2 (0.41) | CYP4F2CYP4A11MMP8PPARAPPARG | |
| SCHEMBL1857286 | 0.85 | LMNA (0.46) | MMP8PPARACPB2PPARGPPARD | |
| SCHEMBL28751620 | 0.85 | LOXL2 (0.39) | MMP8PPARACPB2PPARGPPARD | |
| SCHEMBL4333135 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11MMP8PPARAPPARG | |
| Hydrochloric Acid SCHEMBL4329895 | 0.84 | LOXL2 (0.38) | MMP8PPARACPB2 | |
| SCHEMBL6497419 | 0.82 | CYP19A1 (0.42) | MMP8 | |
| SCHEMBL6506184 | 0.82 | ALOX15 (0.46) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | CYP4F2 792/4885CYP4A11 188/4885MMP8 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.